Arthroscopic surgery is frequently performed in outpatient settings. Postoperative pain is an important outcome of surgery that can result in late discharge to home and limit early rehabilitation. Opioids, nonsteroidal anti-inflammatory drugs, clonidine, neostigmine and magnesium sulphate have been injected intra-articularly, with variable effects ([@b1-prm-20-35]--[@b4-prm-20-35]).

Magnesium is the fourth most common cation in the body. It has important physiological roles in enzymatic activation of energy metabolism and protein synthesis ([@b5-prm-20-35]). Magnesium has also been shown to have antinociceptive effects in animal and human models of chronic pain ([@b6-prm-20-35],[@b7-prm-20-35]). The analgesic properties of magnesium are primarily related to antagonism of the *N*-methyl-D-aspartate (NMDA) receptor and the regulation of calcium influx into cells ([@b6-prm-20-35],[@b8-prm-20-35],[@b9-prm-20-35]). This analgesic effect was first demonstrated in humans in 1996, when magnesium was administered intravenously in the perioperative period ([@b7-prm-20-35]). It has been reported to reduce postoperative analgesic requirements ([@b10-prm-20-35],[@b11-prm-20-35]).

The analgesic efficacy of intra-articular magnesium after knee surgery has been demonstrated; however, its effect after shoulder surgery has not been reported in the literature ([@b4-prm-20-35]). Accordingly, the aim of the present study was to evaluate the potential analgesic effect of magnesium when injected intra-articularly during arthroscopic shoulder surgery.

METHODS
=======

With the approval of the local ethics committee (2009-249) and signed informed patient consent, 67 patients (38 men and 29 women) who were between 18 and 65 years of age, with American Society of Anesthesiologists physical status class I to II, who were scheduled to undergo arthroscopic rotator cuff repair and were able to use a patient-controlled analgesia device (Pain Management Provider; Abbott Laboratories, USA) were included in the present study. Exclusion criteria were: known allergies to one of the study drugs; major hepatic, renal or cardiovascular dysfunction, especially atrioventricular block; and previous treatment with opioids and calcium channel blockers. The Clinical Trial Registration number is ACTRN12613001360707.

All patients were informed about pain evaluation using a visual analogue scale (VAS) before surgery. The 67 patients were randomly assigned to one of two groups using sealed opaque envelopes containing one of the two treatment regimens. When patients arrived at the operating room, they chose one of the envelopes and a nurse who was not involved in the present study opened the envelope and prepared the study drug. In the magnesium group (group M), patients (n=30) received 1000 mg magnesium sulphate (100 mg/mL) intra-articularly in 10 mL saline. Patients in the control group (group C; n=30) received 10 mL saline only.

All patients were premedicated with 0.01 mg/kg intravenous midazolam. After routine monitoring of patients' heart rate, blood pressure (measured noninvasively) and peripheral oxygen saturation, an infusion of 0.9% NaCl (5 mg/kg/h to 7 mg/kg/h) was initiated. All patients were anesthetized using standard protocols with 2 mg/kg to 3 mg/kg propofol, 1 μg/kg to 2 μg/kg fentanyl and 0.5 mg/kg atracurium. Endotracheal intubation was performed when sufficient muscle relaxation was achieved. During the maintenance of anesthesia, 1% to 2% sevoflurane in 40% O~2~ and 60% N~2~O was administered; no supplemental opioids were given during surgery.

All surgical procedures and intra-articular injections were performed by the same surgeon. The same main arthroscopic portal was used for injection and catheter placement at the end of the surgery before extubation of the patient. The catheter was tunnelled 4 cm to 5 cm subcutaneously. Surgical drains were not used in any of the patients. Both the orthopedic surgeon and the attending anesthesiologist were blinded to the drug assignment. The patients were also blinded to the study drug.

Another investigator, who was also blinded to the study drug, performed and recorded measurements at rest and during passive movement of the arm 30° perpendicular anteroposteriorly. Active movement was not evaluated after surgery because it was not permitted by the surgeon during the first 24 h postoperatively. Analgesia was evaluated using a 10-point linear VAS at 1 h, 2 h, 6 h, 8 h, 12 h, 18 h and 24 h after the operation. VAS was evaluated using a 10-point linear ruler-like device. A score of 0 was defined as no pain and a score of 10 as the worst imaginable pain. At the end of the first postoperative hour, intravenous blood sampling was performed to determine serum magnesium levels.

Postoperative analgesia was maintained by intra-articular morphine (0.01%; 10 mg) + bupivacaine (0.5%; 100 mL) patient-controlled analgesia as a 1 mL infusion with a 1 mL bolus dose and 15 min lock-out time; additionally, for VAS scores \>5, intramuscular diclofenac sodium 75 mg was administered as needed during the study period (maximum two times).

Side effects, such as flushing, sedation, nausea, vomiting, bradycardia, tachycardia and decrease in blood pressure \>15% of baseline values, were recorded when the VAS scores were evaluated.

Statistical analysis
--------------------

Data were analyzed using SPSS version 16.0 (IBM Corporation, USA). Numerical variables were examined for normality. Patient characteristics and operative time data were analyzed using the Student's *t* test. VAS data were analyzed using a two-way repeated-measures ANOVA with time and treatment as factors. A post hoc Tukey test was applied to determine significant differences between the treatment and control groups. Descriptive data are expressed as mean ± SD. Sample size was estimated using pain scores as the primary variable. A sample size of 30 patients was deemed to be sufficient to detect a difference of 1 cm on the VAS, as well as an SD of 1 cm at an alpha threshold of 0.007 with 90% power; P\<0.05 was considered to be statistically significant and was adjusted to 0.007 when multiple comparisons were performed, according to Bonferroni.

RESULTS
=======

A total of 67 patients with an American Society of Anesthesiologists physical status class of I or II (38 men and 29 women) underwent arthroscopic shoulder surgery performed by the same surgeon. The results of seven patients (four from group M and three from group C) were not included in the study because of accidental catheter withdrawal in the postoperative period. These patients were excluded from the study after withdrawal of their catheter.

The groups were comparable with regard to age (range 23 to 58 years of age), weight range (56 kg to 98 kg), sex distribution and operation time ([Table 1](#t1-prm-20-35){ref-type="table"}). The mean (± SD) heart rates in groups C and M before induction and during the operation were 76±4.5 beats/min versus 75.1±3.5 beats/min, and 74.1±2.8 beats/min versus 73.4±2.1 beats/min, respectively. The average mean arterial pressure in the control and magnesium groups were 92.4±6.1 mmHg versus 93.3±6.7 mmHg, and 93.7±2.5 mmHg versus 94.4±3.2 mmHg, respectively. There was no significant difference in mean heart rate and arterial pressure between the two groups at any of the time points at which they were measured.

The demographic characteristics and operation times were found to be similar between the groups ([Table 1](#t1-prm-20-35){ref-type="table"}). The total amount of morphine + bupivacaine used in group M was significantly higher than in group C ([Table 2](#t2-prm-20-35){ref-type="table"}). In addition, the total amount of diclofenac sodium needed was significantly higher in group C ([Table 2](#t2-prm-20-35){ref-type="table"}). Postoperative magnesium levels were significantly higher in group M; however, all were within the normal range (657.6 μM to 1068.6 μM)

Pain scores measured at rest 1 h, 2 h, 6 h, 8 h and 12 h after the end of surgery were significantly lower in group M than in group C ([Figure 1](#f1-prm-20-35){ref-type="fig"}). Furthermore, pain scores 1 h, 2 h, 6 h, 8 h and 12 h after the end of surgery during passive motion in group M were significantly lower than in group C ([Figure 2](#f2-prm-20-35){ref-type="fig"}).

In group M, three patients experienced nausea, two experienced vomiting and two exhibited flushing. In group C, two patients experienced nausea and vomiting. Noninvasive blood pressure measurements and heart rate did not change significantly. No patients complained of postoperative effects of sedation.

DISCUSSION
==========

In the present study, intra-articular injections of magnesium were found to have analgesic effects after arthroscopic shoulder surgery. The treatment decreased patients' postoperative bupivacaine + morphine consumption and additional analgesic need after arthroscopic shoulder surgery until 12 h postoperatively with passive movement and at rest.

Arthroscopic shoulder procedures have become common in current orthopedic and anesthetic practice. Although arthroscopic shoulder surgery is less invasive and painful than open shoulder surgery, it can still cause severe postoperative pain. Efficient pain relief is needed for patients' well being, early rehabilitation and faster recovery ([@b12-prm-20-35]).

Interscalene brachial plexus blocks, wound infiltrations and intraarticular injections of various drugs are methods used to decrease postoperative pain ([@b12-prm-20-35],[@b13-prm-20-35]). The advantages of the intra-articular technique are its simplicity and minimal risk for complications.

The peripheral antinociceptive effect of NMDA antagonism have been precisely defined. NMDA antagonists decrease the excitability of C-fibres, which play a role in the central processing of pain ([@b14-prm-20-35]--[@b16-prm-20-35]).

NMDA receptors play an important role in central nociceptive transmission, modulation and sensitization of acute pain states ([@b17-prm-20-35]). NMDA receptors are located centrally and peripherally, in the joints as well as in skin and muscles ([@b14-prm-20-35],[@b18-prm-20-35],[@b19-prm-20-35]), and play a role in sensory transmission of noxious stimuli. Magnesium ions are centrally positioned in NMDA receptors and inactivate the receptors. When an afferent stimulus is present, the resulting depolarization causes the centrally located magnesium ion to move out of the pore of the NMDA receptor, which allows calcium, sodium and potassium ions to flow through the pore ([@b20-prm-20-35]). Magnesium can be considered to be a physiological blocker of NMDA receptors ([@b21-prm-20-35]).

Magnesium has been reported to produce important analgesic effects, including attenuation of neuropathic pain and potentiation of morphine analgesia ([@b6-prm-20-35],[@b22-prm-20-35]). Turan et al ([@b23-prm-20-35]) reported that magnesium improved the overall quality of analgesia and enhanced the anesthesia provided by lidocaine for intravenous regional anesthesia.

The exact mechanism of magnesium analgesia has not been precisely defined. The median effective concentration of magnesium required to block NMDA receptors has been reported to be between 400 μM and 600 μM ([@b16-prm-20-35]). However, the magnesium levels measured postoperatively in the present study were within the normal range -- ie, they were higher than these levels. Although the beneficial effect of magnesium may be its antagonistic effect on NMDA receptors, its effects on calcium channels may also play a role ([@b8-prm-20-35]). In terms of other mechanisms of action of magnesium, the ability of magnesium to block voltage-gated calcium channels is most likely to be relevant in the present study. It has been reported that calcium channel blockers have morphine-enhancing effects in the context of chronic pain ([@b24-prm-20-35]). Elsharnouby et al ([@b25-prm-20-35]) evaluated the analgesic properties of intraarticular magnesium and bupivacaine after arthroscopic knee surgery and concluded that the analgesia effect of magnesium may be due more to pharmacodynamics than a pharmacological receptor effect.

According to the literature, magnesium is used for postoperative pain relief intravenously, intrathecally and epidurally. Perioperative intravenous magnesium can reduce opioid consumption and pain scores in the first 24 h postoperatively, without any reported serious side effects ([@b26-prm-20-35]). Magnesium can be considered to be an efficacious adjunct to postoperative analgesia ([@b4-prm-20-35]).

The analgesic effect of intra-articular magnesium after arthroscopic knee surgery has been evaluated and confirmed in several studies ([@b4-prm-20-35],[@b27-prm-20-35]). Bondok and Abd El-Hady ([@b4-prm-20-35]) reported that intra-articular administration of 500 mg MgSO~4~ at the conclusion of arthroscopic knee surgery improved postoperative pain scores. It also increased the time to the first rescue analgesic request and decreased the need for other analgesic medications. Elsharnouby et al ([@b25-prm-20-35]) concluded that 1000 mg intra-articular magnesium combined with bupivacaine reduced postoperative pain compared with either bupivacaine or magnesium alone, or with a saline placebo. In addition, Koltka et al ([@b27-prm-20-35]) reported that the intra-articular administration of 500 mg MgSO~4~, 100 mg levobupivacaine and 8 mg lornoxicam provided better pain relief and less analgesic requirements following outpatient arthroscopic knee surgery compared with placebos. They found that magnesium decreased postoperative pain scores compared with placebos, although this effect was not statistically significant after 4 h ([@b27-prm-20-35]). In our study, however, analgesia was significantly higher until 12 h postoperatively; both groups were comparable thereafter. The longer duration of analgesia may be due to the higher doses of magnesium, or the presence of more NMDA receptors in shoulder joints. Kamal and Sdeek ([@b28-prm-20-35]) evaluated the effects of intra-articular magnesium (1000 mg; 25 mL), bupivacaine (0.25%; 25 mL) and magnesium + bupivacaine on postoperative analgesia after arthroscopic shoulder surgery and reported that magnesium combined with bupivacaine reduced postoperative analgesic requirements compared with either bupivacaine or magnesium alone. Thus, our results are consistent with those of other studies investigating knee surgery. All patients were discharged after 24 h without any complications. Serum magnesium levels were not evaluated in these studies. According to our results, serum magnesium levels increased after an intra-articular injection of 1000 mg magnesium; however, the increased levels remained within the normal range. In a meta-analysis by Albrecth et al ([@b26-prm-20-35]), measured magnesium levels were also higher compared with placebo groups (mean difference 0.42 mmol/L), but they were unable to find any studies investigating doses in the literature. We could not find any data relating serum concentrations to analgesic properties of magnesium in the literature, although Koinig et al ([@b11-prm-20-35]) reported that decreased intraoperative magnesium levels may explain the increase in analgesic requirements.

There were several limitations to the present study. First, the chondrotoxic effects of magnesium were not evaluated. Second, patients' VAS scores were evaluated for only 24 h, and no long-term data regarding pain and analgesic requirements or complications were obtained. Although there was a risk for catheter infection, the removed catheters were not cultured. None of the patients complained about redness, swelling or discharge at the catheter site.

Although previous research investigating the use of magnesium sulphate intra-articularly reported no serious side effects, it is only licensed for intravenous administration ([@b23-prm-20-35]). Future studies must evaluate the side effects of intra-articular injections of magnesium to ensure its safe use.

CONCLUSION
==========

Magnesium causes a reduction in postoperative pain compared with saline when administered intra-articularly. Further studies comparing the effects of intravenous/intramuscular with intra-articular injections of magnesium at different doses are recommended.
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###### 

Demographic features of patients in the control and magnesium groups

                        **Group**   
  --------------------- ----------- -----------
  Age, years            41.6±10.4   39.8±9.2
  Body weight, kg       76.3±12.4   77.2±11.3
  Male/female, n/n      14/16       17/13
  Operation time, min   72.86±12    74.6±11.3
  ASA I/II, n/n         19/11       13/17

*Data presented as mean* ± *SD unless otherwise indicated. ASA American Society of Anesthesiologists*

###### 

Magnesium level and postoperative consumption of morphine + bupivacaine and diclofenac

                                           **Group**     
  ---------------------------------------- ------------- ----------------------------------------------------------
  Magnesium, μM                            817±78        891.87±12[^\*^](#tfn3-prm-20-35){ref-type="table-fn"}
  Morphine + bupivacaine consumption, mL   58.8±17.8     44.4±16.8[^\*\*^](#tfn4-prm-20-35){ref-type="table-fn"}
  Diclofenac sodium, mg                    95.25±20.25   20.25±9.75[^\*\*^](#tfn4-prm-20-35){ref-type="table-fn"}

Data presented as mean ± SD.

P\<0.05;

P\<0.01
